Effects of RNAi targeting CDX2 gene expression on biological characters of human leukemia cells and its relevant mechanisms / 天津医药

Objective To detect the effects of siRNA targeting CDX2 gene expression on of BCR-ABL, caspase and Bax expressions, and the mechanisms thereof. Methods According to the earlier experiments, siRNA specifically targeting CDX2 gene (CDX2-siRNA) and the negative control sequence (CDX2-siRNA-NC) were selected, and then were transfected into K562 cells by Roche X-tremeGENE HP DNA Transfection Reagent. The flow cytometry analysis was used to detect the effects of siRNA on cell apoptosis. The expressions of BCR-ABL, caspase-9, Bax mRNA and protein were tested by RT-PCR and Western blot assay. Results MTT and flow cytometry analysis showed that after the silence of CDX2 gene expression, the proliferation of K562 cells was prohibited and the apoptotic rate of K562 cells was distinctly increased compared with that of normal cell group, but the negative control group had no significant change. According to the RT-PCR and Western blot assay, in comparison with the normal cell group and the negative control group, the expression levels of BCR-ABL mRNA and protein were obviously decreased, and the difference was statistic significance. On the other hand, the expressions of caspase-9 and Bax mRNA and protein were significantly higher than those of other two groups (P<0.05). Conclusion CDX2-siRNA can promote apoptosis of K562 cells obviously, and the mechanism is related with the down-regulation of BCR-ABL and the up-regulation of caspase-9 and Bax.

The therapeutic improvement of pediatric acute myeloid leukemia / 国际儿科学杂志

Acute myeloid leukemia(AML) is a heterogeneous kind of disease,which is accounting for 15％ ～ 20％ of all tumors diagnosed in children under 15 years of age.In the past few decades,remarkable improvements have been yielded in long-term outcomes for children with AML.A better risk-group stratification of disease,which is based on clinical and biological features,a more effective use of anti-leukemia agents and enormous improvements in supportive care have increased the rate of cure by approximately 60％.This paper review the new improvements in the chemotherapeutic regimens and drugs.